RU2021106383A - Состав для ингибирования образования агонистов 5-ht2b и способы его применения - Google Patents

Состав для ингибирования образования агонистов 5-ht2b и способы его применения Download PDF

Info

Publication number
RU2021106383A
RU2021106383A RU2021106383A RU2021106383A RU2021106383A RU 2021106383 A RU2021106383 A RU 2021106383A RU 2021106383 A RU2021106383 A RU 2021106383A RU 2021106383 A RU2021106383 A RU 2021106383A RU 2021106383 A RU2021106383 A RU 2021106383A
Authority
RU
Russia
Prior art keywords
day
fenfluramine
amount
patient
administration
Prior art date
Application number
RU2021106383A
Other languages
English (en)
Inventor
Стефен Дж. ФАРР
Брукс Бойд
Original Assignee
Зодженикс Интернэшнл Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=59955585&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RU2021106383(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Зодженикс Интернэшнл Лимитед filed Critical Зодженикс Интернэшнл Лимитед
Publication of RU2021106383A publication Critical patent/RU2021106383A/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A61K31/105—Persulfides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Claims (19)

1. Способ уменьшения или облегчения приступов у пациента, включающий:
введение фенфлурамина; и
введение стирипентола, тем самым модулируя образование норфенфлурамина, что приводит к более высоким уровням фенфлурамина, где фенфлурамин для получения эффективной дозы снижается на 30% или более ниже дозы 0,8 мг/кг/день.
2. Способ по п.1, в котором у пациента диагностирован синдром Драве.
3. Способ по п.1, в котором у пациента диагностирована форма рефрактерной эпилепсии, выбранной из группы, состоящей из синдрома Драве, синдрома Леннокса-Гасто, синдрома Дузе и синдрома Веста.
4. Способ по п.1, дополнительно включающий:
совместное введение субъекту эффективного количества сопутствующего лекарственного средства, выбранного из группы, состоящей из ацетазоламида, барбексаклона, бекламида, бриварацетама, бупроприона, цинакалета, клобазама, клоназепама, клоразепата, диазепама, дивалопрекса, эсликарбазепина ацетата, этадиона, этотоина, фелбамата, габапентина, лакозамида, лоразепама, мефенитоина, метазоламида, метсуксимида, метилфенобарбитола, мидазолама, ниметазепама, нитразепама, окскарбазепина, параметадиона, перампанеля, пирацетама, фенацемида, фенетурида, фенсуксимида, фенитоина, калия бромида, прегабалина, примидона, ретигабина, руфинамида, селектрацетама, натрия вальпроата, сультиама, темазепама, тиагабина, топирамата, триметадиона, вальноктамида, вальпромида, вигабатрина, зонисамида, и его фармацевтически приемлемой соли.
5. Способ уменьшения или облегчения приступов у пациента с диагнозом рефрактерной эпилепсии, включающий:
введение пациенту жидкого препарата фенфлурамина в количестве по меньшей мере на 30% меньше обычного в диапазоне от 0,2 мг/кг/день до 0,8 мг/кг/день; и
введение стирипентола в жидком составе в количестве от 0,5 мг/кг/день до 25 мг/кг/день, тем самым модулируя образование норфенфлурамина и приводя к более высоким уровням фенфлурамина.
6. Способ уменьшения или облегчения приступов у пациента с диагнозом рефрактерной формы эпилепсии, включающий:
введение пациенту жидкого препарата фенфлурамина в количестве, которое на 30% меньше, чем эффективное количество в диапазоне от 0,2 мг/кг/день до 0,8 мг/кг/день, из-за одновременного введения стирипентола в жидком составе в количестве от 0,5 мг/кг/день до 25 мг/кг/день, модулируя тем самым образование норфенфлурамина и приводя к более высоким уровням фенфлурамина.
7. Способ по п.6, в котором фенфлурамин вводят в количестве, на 70% меньшем, чем эффективная доза 0,8 мг/кг/день.
8. Способ по п.6, в котором фенфлурамин вводят в количестве 0,56 мг/кг/день или меньше.
9. Способ уменьшения или облегчения приступов у пациента с диагнозом синдрома Драве, включающий:
введение пациенту жидкого препарата фенфлурамина в количестве от 0,2 мг/кг/день до 0,8 мг/кг/день; и
введение стирипентола в жидком составе в количестве от 0,5 мг/кг/день до 25 мг/кг/день, тем самым модулируя образование норфенфлурамина и приводя к более высоким уровням фенфлурамина.
10. Способ уменьшения или облегчения приступов у пациента с диагнозом синдрома Драве, включающий:
введение пациенту жидкого препарата фенфлурамина в количестве, которое на 40% меньше, чем эффективное количество в диапазоне от 0,2 мг/кг/день до 0,8 мг/кг/день, из-за одновременного введения стирипентола в жидком составе в количестве от 0,5 мг/кг/день до 25 мг/кг/день, тем самым модулируя образование норфенфлурамина и приводя к более высоким уровням фенфлурамина.
RU2021106383A 2016-08-24 2017-08-02 Состав для ингибирования образования агонистов 5-ht2b и способы его применения RU2021106383A (ru)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201662379183P 2016-08-24 2016-08-24
US62/379,183 2016-08-24
US201762515383P 2017-06-05 2017-06-05
US62/515,383 2017-06-05

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
RU2019105059A Division RU2746000C2 (ru) 2016-08-24 2017-08-02 Состав для ингибирования образования агонистов 5-ht2b и способы его применения

Publications (1)

Publication Number Publication Date
RU2021106383A true RU2021106383A (ru) 2021-04-05

Family

ID=59955585

Family Applications (2)

Application Number Title Priority Date Filing Date
RU2021106383A RU2021106383A (ru) 2016-08-24 2017-08-02 Состав для ингибирования образования агонистов 5-ht2b и способы его применения
RU2019105059A RU2746000C2 (ru) 2016-08-24 2017-08-02 Состав для ингибирования образования агонистов 5-ht2b и способы его применения

Family Applications After (1)

Application Number Title Priority Date Filing Date
RU2019105059A RU2746000C2 (ru) 2016-08-24 2017-08-02 Состав для ингибирования образования агонистов 5-ht2b и способы его применения

Country Status (14)

Country Link
US (6) US20180055789A1 (ru)
EP (2) EP4201427A1 (ru)
JP (2) JP2019526544A (ru)
KR (2) KR20230021172A (ru)
CN (1) CN109689103A (ru)
AU (3) AU2017315273B2 (ru)
CA (1) CA3032996A1 (ru)
IL (2) IL290727B2 (ru)
MX (2) MX2019001799A (ru)
RU (2) RU2021106383A (ru)
SG (1) SG11201900975XA (ru)
TW (3) TW202308601A (ru)
WO (1) WO2018037306A1 (ru)
ZA (1) ZA201900766B (ru)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9549909B2 (en) 2013-05-03 2017-01-24 The Katholieke Universiteit Leuven Method for the treatment of dravet syndrome
US20170174614A1 (en) 2015-12-22 2017-06-22 Zogenix International Limited Metabolism resistant fenfluramine analogs and methods of using the same
IL286391B (en) 2015-12-22 2022-08-01 Zogenix International Ltd Penfluramine preparations and methods for their preparation
EP4201427A1 (en) 2016-08-24 2023-06-28 Zogenix International Limited Formulation for inhibiting formation of 5-ht 2b agonists and methods of using same
US10682317B2 (en) 2017-09-26 2020-06-16 Zogenix International Limited Ketogenic diet compatible fenfluramine formulation
US20190091179A1 (en) 2017-09-26 2019-03-28 Zogenix International Limited Congnitive function with fenfluramine
GB201715919D0 (en) * 2017-09-29 2017-11-15 Gw Res Ltd use of cannabinoids in the treatment of epilepsy
EP3790537A1 (en) 2018-05-11 2021-03-17 Zogenix International Limited Compositions and methods for treating seizure-induced sudden death
EP3806835A1 (en) 2018-06-14 2021-04-21 Zogenix International Limited Compositions and methods for treating respiratory depression with fenfluramine
WO2019240561A1 (ko) 2018-06-15 2019-12-19 주식회사 엘지화학 장식 부재
WO2020112460A1 (en) * 2018-11-30 2020-06-04 Zogenix International Limited A method of treating refractory epilepsy syndromes using fenfluramine enantiomers
CA3153099A1 (en) 2019-09-17 2021-03-25 Zogenix International Limited Methods of treating epileptic patients with fenfluramine
CN115003289A (zh) * 2019-11-21 2022-09-02 新凯治疗有限公司 大麻二酚和/或考比司他联合药物疗法
TW202200152A (zh) 2020-04-30 2022-01-01 泰合生技藥品股份有限公司 氯巴占(clobazam)經皮傳遞系統及其用途
US11612574B2 (en) 2020-07-17 2023-03-28 Zogenix International Limited Method of treating patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
WO2023101866A1 (en) * 2021-12-01 2023-06-08 Zogenix International Limited Fenfluramine for treatment of conditions associated with spreading depolarization
US11977085B1 (en) 2023-09-05 2024-05-07 Elan Ehrlich Date rape drug detection device and method of using same

Family Cites Families (152)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL270984A (ru) 1960-11-05
US3117160A (en) 1961-07-27 1964-01-07 Pfizer & Co C Aralkylamines
US3198834A (en) 1964-07-27 1965-08-03 Snc Science Union Et Compagnie Optical isomers of trifluoromethylated phenethylamines
GB1254332A (en) 1969-02-27 1971-11-17 Science Union & Cie Amino acids and their derivatives and processes for preparing them
DE2143204C3 (de) 1971-08-28 1979-09-27 Deutsche Gold- Und Silber-Scheideanstalt Vormals Roessler, 6000 Frankfurt N-Fluoralkyl-phenylisopropylamin-Derivate und deren Salze, Verfahren zu deren Herstellung und Arzneimittel auf deren Basis
DE2150399A1 (de) 1971-10-09 1973-04-12 Hoechst Ag Neue oxime
GB1413078A (en) 1973-07-27 1975-11-05 Beecham Group Ltd Process for the production of plus-norfenfluramine and plus-fenfluramine and salts thereof
GB1413070A (en) 1973-07-27 1975-11-05 Beecham Group Ltd Process for the production of - norfenfluramine and - fenfluramine and salts thereof
US4452815A (en) 1980-06-16 1984-06-05 Massachusetts Institute Of Technology Method of utilizing d,l-fenfluramine for modifying feeding behavior
US4309445A (en) 1980-06-16 1982-01-05 Massachusetts Institute Of Technology d-Fenfluramine for modifying feeding behavior
DE3717434C1 (de) 1987-05-23 1988-09-15 Degussa Verfahren zur Herstellung von m-Trifluormethylphenylacetonitril
KR890003368A (ko) 1987-08-06 1989-04-14 원본미기재 특정의 치환된 페닐알킬아미노(및 아미노산) 유도체 및 기타 세로토닌농도 저하제로 오심 및 구토를 치료하는 방법
US4857553A (en) 1987-08-06 1989-08-15 A. H. Robins Company, Incorporated Method of treating nausea and vomiting with certain substituted-phenylalkylamino (and aminoacid) derivatives and other serotonin depleting agents
HU204497B (en) 1989-10-09 1992-01-28 Chinoin Gyogyszer Es Vegyeszet Process for producing phenfluramine
IT1238686B (it) 1990-02-09 1993-09-01 Lab Mag Spa Procedimento per la preparazione di levo e destro fenfluramina
FR2684552B1 (fr) 1991-12-06 1995-04-28 Adir Utilisation de la d-fenfluramine et de derives de la fenfluramine dans le traitement de l'hypertension chez des sujets insulino-resistants.
US5985880A (en) 1996-06-05 1999-11-16 Delta Pharmaceuticals Compositions and methods for reducing respiratory depression and attendant side effects of mu opioid compounds
US5708018A (en) 1993-08-06 1998-01-13 Pharmacia & Upjohn Company 2-aminoindans as selective dopamine D3 ligands
US5834477A (en) 1993-12-08 1998-11-10 The United States Of America As Represented By The Secretary Of The Army Opiate analgesic formulation with improved safety
US5412102A (en) 1994-05-27 1995-05-02 Syntex (U.S.A.) Inc. Processes for preparing 1-butyl-2-[2'-(2H-tetrazol-5-yl) biphenyl-4-ylmethyl]-1H-indole-3-carboxylic acid
WO1995033455A1 (en) 1994-06-03 1995-12-14 Elmaleh David R Meta substituted arylalkylamines and therapeutic and diagnostic uses thereof
IT1298349B1 (it) 1996-05-29 2000-01-05 Alfa Chem Ital Processo per la produzione di 1 - (3-trifluorometil) fenil-propan- 2-one intermedio nella sintesi della fenfluramina
IT1292885B1 (it) 1997-04-28 1999-02-11 Alfa Chem Ital Processo per la produzione degli isomeri (r) ed (s)- alfa -metil-3- (trifluorometil)benzene-etanamina.
EP0920864A1 (en) 1997-12-03 1999-06-09 Pfizer Products Inc. Combination therapy including a specific beta-3 agonist and an anorectic agent
US20020098175A1 (en) 1998-06-16 2002-07-25 Zohoungbogbo Mathias C. Dietetic food composition and dietetic method using such composition
US6045501A (en) 1998-08-28 2000-04-04 Celgene Corporation Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug
DE69907508T2 (de) 1998-12-23 2003-11-20 Orphan Medical Inc Mikrobenbeständige und stabilisierte lösungen, die gamma-hydroxybuttersäuresalze zur behandlung von narkolepsie enthalten
US20080103179A1 (en) 2006-10-27 2008-05-01 Tam Peter Y Combination Therapy
US7124031B1 (en) 2000-05-11 2006-10-17 Medco Health Solutions, Inc. System for monitoring regulation of pharmaceuticals from data structure of medical and labortory records
AU2001275095A1 (en) 2000-07-17 2002-01-30 Opt-E-Scrip, Inc. Single-patient drug trials used with accumulated database
US6315720B1 (en) 2000-10-23 2001-11-13 Celgene Corporation Methods for delivering a drug to a patient while avoiding the occurrence of an adverse side effect known or suspected of being caused by the drug
US7714020B2 (en) 2001-05-24 2010-05-11 Neuren Pharmaceuticals Limited Treatment of non-convulsive seizures in brain injury using G-2-methyl-prolyl glutamate
US7585493B2 (en) 2001-05-24 2009-09-08 Alexza Pharmaceuticals, Inc. Thin-film drug delivery article and method of use
CA2446904A1 (en) 2001-05-24 2003-04-03 Alexza Molecular Delivery Corporation Delivery of drug esters through an inhalation route
NZ530332A (en) 2001-06-22 2005-06-24 Univ Catholique De Louvaine Hydrogel beads or capsules as artificial media for insects oviposition and rearing of endoparasitoids
NZ530889A (en) 2001-07-31 2005-03-24 Wyeth Corp Use of sucralose as a sweetening agent combined with pH modulation of chemical formulations generates enhanced taste-masking effects
AUPR732601A0 (en) 2001-08-28 2001-09-20 Polychip Pharmaceuticals Pty Ltd Methods for the synthesis of amines such as ephedrine and inter mediates
DE60230818D1 (de) 2001-09-24 2009-02-26 Imp Innovations Ltd Pyy3-36 zur zur reduzierung oder vorbeugung von fettleibigkeit
RU2317104C2 (ru) 2001-09-24 2008-02-20 Импиэриэл Инноувейшнс Лимитид Способ модификации пищевого поведения и применение pyy или его агониста в качестве средства для модификации пищевого поведения
US6599901B1 (en) 2001-11-19 2003-07-29 Hoffman-La Roche Inc. Pyridone substituted benzothiazole derivatives
US7101572B2 (en) 2001-12-07 2006-09-05 Unilab Pharmatech, Ltd. Taste masked aqueous liquid pharmaceutical composition
NZ534757A (en) 2002-03-12 2006-07-28 Merck & Co Inc Substituted amides
JP2005531520A (ja) 2002-03-28 2005-10-20 メルク　エンド　カムパニー　インコーポレーテッド 置換２，３−ジフェニルピリジン類
US7668730B2 (en) 2002-12-17 2010-02-23 JPI Commercial, LLC. Sensitive drug distribution system and method
WO2005004865A1 (en) 2003-07-08 2005-01-20 Georg-August-Universität Göttingen Use of 5-ht4(a)-serotonin receptor agonists
GB0410266D0 (en) 2004-05-07 2004-06-09 Ketocytonyx Inc Treatment of apoptosis
US20050260610A1 (en) 2004-05-20 2005-11-24 Kurtz Richard E Method for diagnosing and prescribing a regimen of therapy for human health risk
US9820658B2 (en) 2006-06-30 2017-11-21 Bao Q. Tran Systems and methods for providing interoperability among healthcare devices
WO2006034465A1 (en) 2004-09-23 2006-03-30 Merz Pharma Gmbh & Co. Kgaa Memantine for the treatment of childhood behavioral disorders
WO2006100676A2 (en) 2005-03-21 2006-09-28 Health-Smart Limited System for continuous blood pressure monitoring
CN101257889A (zh) 2005-05-25 2008-09-03 詹森药业有限公司 托吡酯的儿科制剂
EP1904630A4 (en) 2005-06-16 2009-10-21 Bionomics Ltd METHODS OF TREATING AND DIAGNOSING EPILEPSY BY DETECTING MUTATIONS OF THE SCN1A GENE
GB0515090D0 (en) 2005-07-22 2005-08-31 Birmingham Res & Dev Ltd Novel epilepsy treatment
WO2007031846A2 (en) 2005-09-14 2007-03-22 University Of The Witwatersrand, Johannesburg Pharmaceutical composition
US8109891B2 (en) 2005-09-19 2012-02-07 Biolert Ltd Device and method for detecting an epileptic event
CA2911569C (en) 2005-11-29 2019-11-26 Children's Hospital Medical Center Optimization and individualization of medication selection and dosing
US7592461B2 (en) 2005-12-21 2009-09-22 Bristol-Myers Squibb Company Indane modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
WO2007079181A2 (en) 2005-12-28 2007-07-12 Neurovista Corporation Methods and systems for recommending an action to a patient for managing epilepsy and other neurological disorders
US20090005361A1 (en) 2006-02-06 2009-01-01 Randy Lee Webb Combination of Organic Compounds
DE102006030113B4 (de) 2006-06-28 2009-02-12 Chemische Fabrik Budenheim Kg Graphitfreier Hochtemperatur-Schmierstoff
US8039468B2 (en) 2006-08-31 2011-10-18 The Governors Of The University Of Alberta Method of inhibition of respiratory depression using positive allosteric AMPA receptor modulators
EP2066664A1 (en) * 2006-09-22 2009-06-10 Novartis AG Heterocyclic organic compounds
US20080183498A1 (en) 2007-01-31 2008-07-31 Quintiles Transnational Corp., Inc. Methods and systems for site startup
EP2139467B1 (en) 2007-02-08 2016-09-21 Biogen MA Inc. Neuroprotection in demyelinating diseases
WO2008104524A1 (en) 2007-02-28 2008-09-04 Smithkline Beecham Corporation Thiadiazole derivatives, inhibitors of stearoyl-coa desaturase
US20100297181A1 (en) * 2007-12-26 2010-11-25 Eisai R&D Management Co., Ltd. AMPA Receptor Antagonists for Epilepsy, Mental Disorders or Deficits in Sensory Organ
GB2456183A (en) 2008-01-04 2009-07-08 Gw Pharma Ltd Anti-psychotic composition comprising cannabinoids and anti-psychotic medicament
JP5714910B2 (ja) 2008-01-09 2015-05-07 チャールストン ラボラトリーズ，インコーポレイテッド 薬学的組成物
EP2331088A4 (en) 2008-08-06 2011-10-12 Gosforth Ct Holdings Pty Ltd COMPOSITIONS AND METHODS FOR TREATING PSYCHIATRIC ILLNESSES
WO2010020585A1 (en) 2008-08-18 2010-02-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Serotonin reuptake inhibitors for the treatment of rett syndrome
PE20110291A1 (es) 2008-09-05 2011-06-04 Gruenenthal Chemie Combinacion farmaceutica de 3-(3-dimetilamino-1-etil-2-metil-propil)-fenol y un antiepileptico
US8386274B1 (en) 2008-09-17 2013-02-26 Mckesson Financial Holdings Limited Systems and methods for a prescription safety network utilizing eligibility verification transactions
GEP20135723B (en) 2008-10-09 2013-01-10 Acraf Liquid pharmaceutical composition containing paracetamol
CA2776945A1 (en) 2008-10-10 2010-04-15 The United States Of America, As Represented By The Secretary Of The Arm Y, On Behalf Of Walter Reed Army Institute Of Research Methods and compositions for treating status epilepticus and seizures causing status epilepticus
TWI503101B (zh) 2008-12-15 2015-10-11 Proteus Digital Health Inc 與身體有關的接收器及其方法
EP2406765A4 (en) 2009-03-09 2014-12-31 Celgene Corp DEVICE FOR ADMINISTERING A MEDICAMENT TO A PATIENT WITH RESTRICTED PATIENT-SIDED ACCESS TO THE MEDICAMENT IN THE CASE OF CONTRAINDICATIONS AND APPLICATION METHOD THEREFOR
WO2010121022A1 (en) 2009-04-15 2010-10-21 Research Triangle Institute Monoamine reuptake inhibitors
US20100324936A1 (en) 2009-04-22 2010-12-23 Suresh-Kumar Venkata Vishnubhatla Pharmacy management and administration with bedside real-time medical event data collection
US9453027B2 (en) 2009-07-27 2016-09-27 Daljit Singh Dhanoa Deuterium-enriched pyridinonecarboxamides and derivatives
AR079862A1 (es) 2010-01-08 2012-02-22 Eurand Inc Composicion de topiramato con sabor enmascarado, un comprimido desintegrable oralmente que comprende la misma y metodo de preparacion
US9251493B2 (en) 2010-03-09 2016-02-02 Perceptimed, Inc. Medication verification and dispensing
WO2011119227A2 (en) 2010-03-25 2011-09-29 Columbia Northwest Pharmaceuticals, Llc Compositions for the treatment of central nervous system disorders including depression employing novel drug combination therapy to reduce suicidality in patients
JP2011221623A (ja) 2010-04-06 2011-11-04 Kakimori Suri 在宅診療支援システム及び方法
ES2687095T3 (es) 2010-05-21 2018-10-23 Research Triangle Institute Fenilimorfolinas y análogos de las mismas
EP2399513B1 (en) 2010-06-23 2017-01-04 Qatar University Qstp-B System for non-invasive automated monitoring, detection, analysis, characterisation, prediction or prevention of seizures and movement disorder symptoms
CA2805760A1 (en) * 2010-07-30 2012-02-02 Merck Sharp & Dohme Corp. Inhibition of cyp3a drug metabolism
SG188362A1 (en) 2010-09-01 2013-04-30 Arena Pharm Inc Modified-release dosage forms of 5-ht2c agonists useful for weight management
US20120270848A1 (en) 2010-10-22 2012-10-25 Galleon Pharmaceuticals, Inc. Novel Compositions and Therapeutic Methods Using Same
WO2012056402A2 (en) 2010-10-26 2012-05-03 Alpharma Pharmaceuticals, Llc Formulations and methods for attenuating respiratory depression induced by opioid overdose
RU103209U1 (ru) 2010-10-29 2011-03-27 Общество С Ограниченной Ответственностью "Правовое Сопровождение Бизнеса" Клиническая информационная система
GB2487712B (en) * 2011-01-04 2015-10-28 Otsuka Pharma Co Ltd Use of the phytocannabinoid cannabidiol (CBD) in combination with a standard anti-epileptic drug (SAED) in the treatment of epilepsy
JP5693325B2 (ja) 2011-03-29 2015-04-01 小林クリエイト株式会社 健診結果出力システム及び健診結果出力プログラム
GB201111712D0 (en) 2011-07-08 2011-08-24 Gosforth Ct Holdings Pty Ltd Pharmaceutical compositions
US10092750B2 (en) 2011-11-11 2018-10-09 Neuroenabling Technologies, Inc. Transcutaneous neuromodulation system and methods of using same
WO2013096878A1 (en) 2011-12-22 2013-06-27 University Of Idaho Garcinia buchananii baker compounds, compositions and related methods
CA2862816A1 (en) 2012-01-27 2013-08-01 Catalyst Pharmaceutical Partners Method of treating tourette's disorder with gaba-aminotransferase inactivators
WO2013122897A1 (en) 2012-02-13 2013-08-22 Amgen Inc. Dihydrobenzoxazine and tetrahydroquinoxaline sodium channel inhibitors
US20130218586A1 (en) 2012-02-21 2013-08-22 Frederic J. Huser Methods and elements for identifying the appropriate patient populations who can safely use prescription chronic care drugs that are switched to an over-the-counter regulatory status
JP6075973B2 (ja) 2012-06-04 2017-02-08 富士通株式会社 健康状態判定装置およびその作動方法
DE102012213040B4 (de) * 2012-07-25 2014-03-20 Infineon Technologies Ag Decoder für physikalisch nicht klonbare Funktionen mittels Schwellendekodierung und entsprechendes Verfahren
CN104918923A (zh) 2012-11-15 2015-09-16 加林制药公司 新型口服生物可利用的呼吸控制调节化合物及其使用方法
WO2014106825A2 (en) 2013-01-06 2014-07-10 Jonathan Rabinowitz Methods and devices for identifying improper medical reporting
US9549909B2 (en) 2013-05-03 2017-01-24 The Katholieke Universiteit Leuven Method for the treatment of dravet syndrome
EP3024463B1 (en) 2013-07-25 2020-03-25 Neuren Pharmaceuticals Limited Neuroprotective bicyclic compounds and methods for their use in treating autism spectrum disorders and neurodevelopmental disorders
PT3035926T (pt) 2013-08-19 2020-09-01 Univ California Compostos e métodos para tratar um distúrbio epiléptico
WO2015066344A1 (en) 2013-11-01 2015-05-07 Arena Pharmaceuticals, Inc. 5-ht2c receptor agonists and compositions and methods of use
US20150141415A1 (en) 2013-11-20 2015-05-21 Omonike Arike Olaleye Methionine Aminopeptidase Inhibitors for Treating Infectious Diseases
JP6147676B2 (ja) * 2014-01-07 2017-06-14 東芝テック株式会社 情報処理装置、店舗システム及びプログラム
CN103886415A (zh) 2014-03-25 2014-06-25 北京蝶禾谊安信息技术有限公司 药品管理方法和装置
EP3136101B1 (en) 2014-04-22 2019-12-25 Tohoku University Method of testing for pulmonary hypertension
GB2530001B (en) * 2014-06-17 2019-01-16 Gw Pharma Ltd Use of cannabidiol in the reduction of convulsive seizure frequency in treatment-resistant epilepsy
WO2016003966A1 (en) 2014-06-30 2016-01-07 University Of Cincinnati Non-invasive detection of spreading depolarization using scalp electroencephalography
NZ730560A (en) 2014-09-29 2020-05-29 Zogenix International Ltd Control system for control of distribution of medication
GB2531282A (en) * 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabinoids in the treatment of epilepsy
WO2016127170A1 (en) 2015-02-06 2016-08-11 Marinus Pharmaceuticals, Inc. Intravenous ganaxolone formulations and their use in treating status epilepticus and other seizure disorders
PL3261640T3 (pl) 2015-02-25 2022-10-31 The Regents Of The University Of California Agoniści 5ht do leczenia zaburzeń padaczkowych
US10292996B2 (en) 2015-03-26 2019-05-21 The Trustees Of Columbia University In The City Of New York Deoxyribonucleoside monophospate bypass therapy for mitochondrial DNA depletion syndrome
JP6668045B2 (ja) 2015-05-15 2020-03-18 ゾゲニクス インターナショナル リミテッド ドラベ症候群を処置するための選択的５−ｈｔ受容体アゴニストおよびアンタゴニスト
HUE046399T2 (hu) 2015-06-17 2020-03-30 Univ Columbia Deoxinukleozid terápia kiegyensúlyozatlan nukleotid pool által okozott betegségek, ideértve a mitokondriális DNS depléciós szindrómát, kezelésére
WO2017003822A1 (en) 2015-06-30 2017-01-05 Galleon Pharmaceuticals, Inc. Novel breathing control modulating compounds, and methods of making and using same
EP3324975B1 (en) 2015-07-22 2022-05-18 John Hsu Composition comprising a therapeutic agent and a respiratory stimulant and methods for the use thereof
WO2017035267A1 (en) 2015-08-24 2017-03-02 Zogenix International Limited Methods of treating lennox-gastaut syndrome using fenfluramine
US20220193082A1 (en) 2015-09-14 2022-06-23 Zogenix International Limited Combination treatment of specific forms of epilepsy
US20170071949A1 (en) 2015-09-14 2017-03-16 Zogenix International Limited Combination treatment of specific forms of epilepsy
EP3170807B1 (en) 2015-11-23 2019-12-11 Frau Pharma S.r.l. New method for synthesis of fenfluramine
US20170174614A1 (en) 2015-12-22 2017-06-22 Zogenix International Limited Metabolism resistant fenfluramine analogs and methods of using the same
IL286391B (en) 2015-12-22 2022-08-01 Zogenix International Ltd Penfluramine preparations and methods for their preparation
WO2017122701A1 (ja) 2016-01-14 2017-07-20 旭硝子株式会社 フッ素樹脂含有溶液、フッ素樹脂含有溶液の製造方法、塗料組成物および塗装物品
JP7002444B2 (ja) 2016-03-28 2022-01-20 武田薬品工業株式会社 医薬
EP4201427A1 (en) 2016-08-24 2023-06-28 Zogenix International Limited Formulation for inhibiting formation of 5-ht 2b agonists and methods of using same
US20190083425A1 (en) 2016-08-24 2019-03-21 Zogenix International Limited Formulation for inhibiting formation of 5-ht2b agonists and methods of using same
US20180092864A1 (en) 2016-09-30 2018-04-05 Zogenix International Limited Compositions and methods for treating seizure disorders
US20200000757A1 (en) 2017-02-08 2020-01-02 Ovid Therapeutics Inc. Methods of treating seizure disorders and prader-willi syndrome
BR112019023483A2 (pt) 2017-05-09 2020-06-30 Zogenix International Limited composição farmacêutica para uso no tratamento, na prevenção e/ou no melhoramento dos sintomas da síndrome de doose, e, kit para tratar, prevenir e/ou melhorar um sintoma da síndrome de doose
US20190091174A1 (en) 2017-09-26 2019-03-28 Zogenix International Limited Method of reducing seizure type experienced by a dravet patient
US10682317B2 (en) 2017-09-26 2020-06-16 Zogenix International Limited Ketogenic diet compatible fenfluramine formulation
US20190091179A1 (en) 2017-09-26 2019-03-28 Zogenix International Limited Congnitive function with fenfluramine
US20190247333A1 (en) 2017-09-26 2019-08-15 Zogenix International Limited Method of reduction in convulsive seizure frequency
WO2019067413A1 (en) 2017-09-26 2019-04-04 Zogenix International Limited USE OF A FENFLURAMINE FORMULATION TO REDUCE THE NUMBER AND FREQUENCIES OF CONVULSIVE CRISES IN PATIENT POPULATIONS
US11352882B2 (en) 2018-03-12 2022-06-07 Cameron International Corporation Plug assembly for a mineral extraction system
MX2020010994A (es) 2018-04-18 2021-01-08 Univ Columbia Terapia de gen para enfermedades causadas por combinaciones desequilibradas de nucleótidos que incluyen síndromes de agotamiento de adn mitocondrial.
EP3790537A1 (en) 2018-05-11 2021-03-17 Zogenix International Limited Compositions and methods for treating seizure-induced sudden death
EP3806835A1 (en) 2018-06-14 2021-04-21 Zogenix International Limited Compositions and methods for treating respiratory depression with fenfluramine
WO2020014075A1 (en) 2018-07-10 2020-01-16 Zogenix International Limited Fenfluramine for use for treating epilepsy or epileptic encephalopathy in patients without pulmonary hypertension
MA53329A (fr) 2018-07-27 2022-03-02 Xenon Pharmaceuticals Inc Méthodes de traitement de l'épilepsie
WO2020105005A1 (en) 2018-11-19 2020-05-28 Zogenix International Limited Methods of treating rett syndrome using fenfluramine
WO2020112460A1 (en) 2018-11-30 2020-06-04 Zogenix International Limited A method of treating refractory epilepsy syndromes using fenfluramine enantiomers
US20220133652A1 (en) 2019-02-25 2022-05-05 Zogenix International Limited A formulation for improving seizure control
US20210299064A1 (en) 2020-02-05 2021-09-30 Zogenix International Limited Method of treating patients with lennox-gastaut syndrome
US11612574B2 (en) 2020-07-17 2023-03-28 Zogenix International Limited Method of treating patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
US20220096514A1 (en) 2020-09-29 2022-03-31 Zogenix International Limited Methods of treating thymidine kinase 2 deficiency by administering deoxycytidine and deoxythymidine
WO2023034115A1 (en) 2021-09-01 2023-03-09 Zogenix International Limited Fenfluramine for treatment of demyelinating diseases and conditions

Also Published As

Publication number Publication date
US11040018B2 (en) 2021-06-22
ZA201900766B (en) 2020-10-28
TWI776407B (zh) 2022-09-01
SG11201900975XA (en) 2019-03-28
IL290727B1 (en) 2023-08-01
US20220125743A1 (en) 2022-04-28
IL290727B2 (en) 2023-12-01
US20190083424A1 (en) 2019-03-21
JP2022180461A (ja) 2022-12-06
WO2018037306A1 (en) 2018-03-01
RU2019105059A (ru) 2020-09-25
AU2017315273B2 (en) 2021-04-29
JP2019526544A (ja) 2019-09-19
MX2019001799A (es) 2019-06-13
IL264637B (en) 2022-04-01
RU2019105059A3 (ru) 2020-11-25
RU2746000C2 (ru) 2021-04-05
US20180055789A1 (en) 2018-03-01
AU2022279469B2 (en) 2024-05-02
US11786487B2 (en) 2023-10-17
EP3518975A1 (en) 2019-08-07
TWI722233B (zh) 2021-03-21
IL290727A (en) 2022-04-01
AU2021204250A1 (en) 2021-07-22
US11759440B2 (en) 2023-09-19
TW202308601A (zh) 2023-03-01
KR20190040237A (ko) 2019-04-17
TW201821071A (zh) 2018-06-16
AU2017315273A1 (en) 2019-03-07
TW202131908A (zh) 2021-09-01
EP4201427A1 (en) 2023-06-28
MX2023005140A (es) 2023-05-26
US20210393550A1 (en) 2021-12-23
AU2022279469A1 (en) 2023-02-02
CA3032996A1 (en) 2018-03-01
CN109689103A (zh) 2019-04-26
US10603290B2 (en) 2020-03-31
US11406606B2 (en) 2022-08-09
US20200246281A1 (en) 2020-08-06
KR20230021172A (ko) 2023-02-13
AU2021204250B2 (en) 2022-09-01
NZ750691A (en) 2021-06-25
US20210267916A1 (en) 2021-09-02

Similar Documents

Publication Publication Date Title
RU2021106383A (ru) Состав для ингибирования образования агонистов 5-ht2b и способы его применения
IL257944A (en) Methods for treating developmental disorders using pipadrol
JP2016518387A5 (ru)
JP2013505205A5 (ru)
MX2020003381A (es) Composicion para la prevencion o el tratamiento de enfermedades relacionadas con el factor de necrosis tumoral (tnf), que contiene un nuevo derivado como ingrediente activo, y metodo para inhibir la actividad del factor de necrosis tumoral (tnf) mediante el uso de la misma.
RU2018108202A (ru) Способы лечения синдрома леннокса-гасто с использованием фенфлурамина
Chun et al. Efficacy of palonosetron for the prevention of postoperative nausea and vomiting: a randomized, double-blinded, placebo-controlled trial
WO2013158680A3 (en) Compositions and methods comprising celecoxib or related compounds and dextromethorphan
DE69832712D1 (de) Analgetische zusammensetzung enthaltend antiepileptische arzneistoffe und deren verwendungen
JP2013509435A5 (ru)
UA96302C2 (en) Solid dosage form comprising 2-ethoxy-1-{[2'-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl]methyl}-1h-benzimidazole-7-carboxylic acid
RS53491B1 (en) Compositions for the treatment of centrally mediated nausea and vomiting
NZ734152A (en) Compounds, compositions and methods useful for cholesterol mobilisation
HK1127289A1 (en) Pharmaceutical combination comprising 3-(3-dimethylamino-1-ethyl-2-methyl- propyl) -phenol and paracetamol
SI2501234T1 (en) METHODS AND INGREDIENTS FOR TREATMENT OF SYMPTOMS RELATED TO POST-TRAUMATIC STRESS EMISSIONS WITH THE USE OF CYCLOBENZAPRINE
JP2013518914A5 (ru)
JP2019517469A5 (ru)
MX2018000084A (es) Una composicion farmaceutica que comprende amlodipino, valsartan y rosuvastatina.
MX345656B (es) (piridin-4-il)bencilamidas como moduladores alostericos de nachr alfa 7.
RU2016132762A (ru) Фармацевтические композиции, содержащие 15-гэпк, и способы лечения астмы и заболеваний легких с их применением
JP2005519936A5 (ru)
CN106668160A (zh) 治慢性鼻炎外用中医配方
RU2015128915A (ru) Составы лоразепама с замедленным высвобождением
RU2013126798A (ru) Комбинированная терапия дексаметазоном
MX2021000312A (es) Composicion farmaceutica que contiene un peptido.